medicine-news-1/unprecedented-merger-occurs-in-retained-physician-search-industry-47441-1/;/a><br

Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3

[0] Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference [0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products [0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES [0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices

Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2 Hand Surgeons Take Ethics into Their Own Hands 3 Hand Surgeons Take Ethics into Their Own Hands 4 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4 H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 1 H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 2 H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 3 Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 1 Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 2 PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 1 PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 2

[0] Hand Surgeons Take Ethics into Their Own Hands [0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug [0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology